New TTS stent will allow physicians to provide precise treatment under direct scope visualisation
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the commercial launch of HANAROSTENT Esophagus TTS self-expanding metal stents (SEMS) made by MI Tech and distributed exclusively through Olympus in the US.
The Through-the-Scope (TTS) oesophageal stent, the newest addition to the Olympus self-expanding stent portfolio, helps to achieve luminal patency in a variety of clinical applications and is designed for use in palliative treatment of oesophageal stricture and/or trachea-oesophageal fistula caused by malignant tumours. The stent offers a fully covered or partially covered option.
“From the first cases in which I’ve used it, I found the HANAROSTENT Esophagus TTS stent to effectively palliate the symptoms of our patients with advanced oesophageal cancer,” said Dr Sandeep Patel, a gastroenterologist at UT Health San Antonio. “The hook-cross nitinol design of the TTS stents allows for accurate and efficient placement with increased patient comfort.”
Pre-loaded into the delivery system, the HANAROSTENT Esophagus TTS fits down the working channel of a standard therapeutic gastroscope and is deployed for placement in the oesophagus. The hook-and-cross nitinol design, unique to HANAROSTENT products, was designed with patient comfort in mind and enables optimal radial and axial force allowing for the flexibility to conform to a patient’s anatomy and precisely target the stricture.
Unlike over-the-wire oesophageal stents, the new 10.5F HANAROSTENT Esophagus TTS allows for accurate and easy oesophageal stenting under direct endoscopic visualisation. Additional benefits of the new oesophageal stent include:
- Minimised use of fluoroscopy: Direct visualisation of the lumen allows physicians to place the stent with reduced dependence on fluoroscopy.
- Increased procedural efficiency: Through-the-Scope application allows for fewer scope/device exchanges, leading to increased efficiency and potential reduction of procedure time.
- Unique wire structure: Hook-and-cross nitinol design provides optimal radial and axial force aimed to minimise the impact of retrosternal pressure, which can be painful to patients.
- Intuitive delivery system: Long delivery length options, ability to fully recapture stent up to a point-of-no-return, as well as a retrieval lasso for stent repositioning combine to allow for safety and precision of placement for users of all experience levels.
“We are pleased with the positive clinical feedback we have received from our trusted physician customers since our limited launch of HANAROSTENT Esophagus TTS in July,” said Kevin Mancini, Vice President for Endoscopy, Olympus America. “We are confident the HANAROSTENT Esophagus TTS will help our physician customers address quality of life issues in patients suffering from advanced gastrointestinal disease.”
“Through our valued partnership with Olympus, the HANAROSTENT Esophagus TTS is the sixth stent successfully launched in the US market in the past two years,” said Jin-Hyung Park, CEO, MI Tech Co. “We are thrilled to continue expanding capabilities of physicians in the US and across the world, through the combination of a line of unparalleled stents and the trusted Olympus brand.”